Skip to main content
OpenTrials
Completed

NCT Number: NCT01025700

Nabilone & Marijuana Addiction

Safety of Nabilone in reducing marijuana craving

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Marijuana Smoking Behavior Chemically-Induced Disorders Marijuana Abuse Marijuana Use Mental Disorders Smoking Smoking, Non-Tobacco Products Substance-Related Disorders

Age range

19 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Vancouver General Hospital - Psychiatry Outpatient

Vancouver, British Columbia, Canada

About this study

Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 19 years or older
  • History of marijuana use

Treatment and study plan

Cesemat

Drug

1 mg capsule per day for 21 days

Other names: Nabilone

Primary outcomes

  1. Safety and tolerability to Nabilone

Secondary outcomes

  1. Marijuana craving questionnaire

Sponsors and collaborators

Lead sponsor

University of British Columbia

Other

Registry information

Official study title

A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Dec 3, 2009
Registry last updated
Feb 17, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.